Considerations To Know About Sifalimumab
MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review To guage several intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Key demo targets were To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis individuals, wh